Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 4/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL16161323 | 1.00 | TP53 (0.58) | TP53SPHK1CA2LAP3OPRM1 | |
| Sulfuric Acid SCHEMBL4377467 | 1.00 | TP53 (0.58) | TP53SPHK1CA2LAP3OPRM1 | |
| Sulfuric Acid SCHEMBL2558701 | 1.00 | TP53 (0.58) | TP53SPHK1CA2LAP3OPRM1 | |
| Sulfuric Acid SCHEMBL26929294 | 1.00 | TP53 (0.58) | TP53SPHK1CA2LAP3OPRM1 | |
| Sulfuric Acid SCHEMBL4366030 | 1.00 | TP53 (0.58) | TP53SPHK1CA2LAP3OPRM1 | |
| Sulfuric Acid SCHEMBL2139560 | 1.00 | TP53 (0.58) | TP53SPHK1CA2LAP3OPRM1 | |
| Sulfuric Acid SCHEMBL7635942 | 0.91 | TP53 (0.49) | TP53SPHK1CA2LAP3OPRM1 | |
| Trifluoromethanesulfonic Acid SCHEMBL18577838 | 0.90 | TP53 (0.47) | TP53SPHK1CA2LAP3OPRM1 | |
| SCHEMBL10822298 | 0.90 | TP53 (0.47) | TP53SPHK1CA2LAP3OPRM1 | |
| SCHEMBL14840204 | 0.90 | TP53 (0.47) | TP53SPHK1CA2LAP3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241005-A1 | Encapsulation of cannabinoids | PRECISIOBIOTIX TECHNOLOGIES INC. (CA) | 2023-08-03 | — | — | US | claimed |
| US-7541312-B2 | Porous carbons from carbohydrates | TDA RESEARCH, INC. (US) | 2009-06-02 | — | — | US | claimed |
| US-20050207962-A1 | Porous carbons from carbohydrates | TDA RESEARCH, INC. (US) | 2005-09-22 | — | — | US | claimed |
| US-20240325316-A1 | Encapsulation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | PRECISIO BIOTIX THERAPEUTICS INC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240238570-A1 | METHODS FOR BETTER DELIVERY OF ACTIVE AGENTS TO TUMORS | SOFUSA HOLDINGS LLC | 2024-07-18 | — | — | US | disclosed |
| US-20240181235-A1 | METHODS FOR LYMPHATIC DELIVERY OF ACTIVE AGENTS | SOFUSA HOLDINGS LLC | 2024-06-06 | — | — | US | disclosed |
| US-11911463-B2 | Topical hyper-allergenic composition and method of treating using the same | ALLEAMIT INC. | 2024-02-27 | — | — | US | disclosed |
| US-20230241005-A1 | Encapsulation of cannabinoids | PRECISIOBIOTIX TECHNOLOGIES INC. (CA) | 2023-08-03 | — | — | US | disclosed |
| US-11607407-B2 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | RELMADA THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3925599-A1 | METHODS FOR BETTER DELIVERY OF ACTIVE AGENTS TO TUMORS | Sorrento Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3922238-A1 | METHODS FOR LYMPHATIC DELIVERY OF ACTIVE AGENTS | Sorrento Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20120164052-A1 | SPHERICAL ORGANIC POLYMER-SILICON COMPOUND COMPOSITE PARTICLES, HOLLOW PARTICLES AND THEIR PRODUCTION METHODS | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2012-06-28 | — | — | US | disclosed |
| WO-2011130455-A1 | DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2',6'-PIPECOLOXYLIDIDE AND METHOD OF USE | BABUL NAJIB (US) | 2011-10-20 | — | — | WO | disclosed |
| US-7854922-B2 | Skin preparation for external use characterized by containing sugar derivative of α, α-trehalose | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100204342-A1 | SPHERICAL ORGANIC POLYMER-SILICON COMPOUND COMPOSITE PARTICLES, HOLLOW PARTICLES AND THEIR PRODUCTION METHODS | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20070140984-A1 | Functional powdery product | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070003502-A1 | Skin preparation for external use characterized by containing sugar derivative of alpha, alpha-trehalose | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1731134-A1 | FUNCTIONAL POWDERS | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2006-12-13 | — | — | EP | disclosed |
| CN-1708310-A | Anticancer or antiviral composition | LAE-OK PARK (KR) | 2005-12-14 | — | — | CN | disclosed |
| EP-1600143-A1 | SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11607407-B2 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | PIP4K2C, PIP5K1C, PIP4K2A | OPRM1 4125/4885TP53 1986/4885SPHK1 1264/4885 |
| US-20240325316-A1 | Encapsulation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | PTGES, PTGS2, PTGS1 | OPRM1 1392/4885TP53 2407/4885SPHK1 3436/4885 |
| US-20230241005-A1 | Encapsulation of cannabinoids | CNR2, CNR1, FAAH | OPRM1 5/4885TP53 4209/4885SPHK1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.